ESMO 2025：基石药业-B 揭晓 CS2009(PD-1/VEGF/CTLA-4 三特异性抗体)Ⅰ期临床试验数据

Zhitong
2025.10.20 01:03
portai
我是 PortAI，我可以总结文章信息。

According to the Zhitong Finance APP, CSTONE PHARMA-B announced that the company will present preliminary data from the Phase I clinical study of CS2009 (PD1/VEGF/CTLA-4 tri-specific antibody) and the design of the Phase Ib clinical study of CS5001 (ROR1 antibody-drug conjugate ADC) for the first time at the 2025 European Society for Medical Oncology (ESMO) annual meeting

Zhitong Finance APP news, CSTONE PHARMA-B (02616) announced that the company will present preliminary data from the Phase I clinical study of CS2009 (PD1/VEGF/CTLA-4 tri-specific antibody) and the design of the Phase Ib clinical study of CS5001 (ROR1 antibody-drug conjugate ADC) for the first time at the 2025 European Society for Medical Oncology (ESMO) annual meeting

来源：Zhitong 本文版权归属原作者/机构所有。
当前内容仅代表作者观点，与本平台立场无关。内容仅供投资者参考，亦不构成任何投资建议。如对本平台提供的内容服务有任何疑问或建议，请联系我们。